Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Rigouts

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Antimicrobial Agents and Chemotherapy|March 16, 2021
Thin-Layer-Agar-Based Direct Phenotypic Drug Susceptibility Testing on Sputum in Eswatini Rapidly Detects Mycobacterium tuberculosis Growth and Rifampicin Resistance Otherwise Missed by WHO-Endorsed Diagnostic TestsE Ardizzoni, E Ariza, D Mulengwa, et al.
Antimicrobial Agents and Chemotherapy|April 9, 2025
Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis-experiences from ArmeniaE Ardizzoni, W Mulders, M De Diego Fuertes, et al.
Journal of Clinical Microbiology|March 3, 2025
Direct thin-layer agar for bedaquiline-susceptibility testing of <i>Mycobacterium tuberculosis</i> at BSL2 level yields high accuracy in 15 days from sputum processingI Cuella-Martin, D Runyambo, S De Bock, et al.
Journal of Clinical Microbiology|September 10, 2020
Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical StrainsS Battaglia, A Spitaleri, A M Cabibbe, et al.
IJTLD Open|August 18, 2025
Using linezolid as a substitute for the injectable in case of ototoxicity is safer and as effective as all-oral treatment for rifampicin-resistant TBM B Souleymane, T Decroo, A Soumana, et al.
IJTLD Open|January 19, 2026
Fifteen years of rifampicin-resistant TB control in Niger: high countrywide treatment uptake and successI Maman Lawan, T Decroo, M B Souleymane, et al.
IJTLD Open|November 17, 2025
High-dose amikacin in the first week of all-oral rifampicin-resistant TB treatment is safe: a single-arm trialJ Snobre, J Gasana, T Decroo, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|April 2, 2020
Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in RwandaJ-C S Ngabonziza, Y M Habimana, T Decroo, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 7, 2021
Effectiveness of GenoType MTBDR<i>sl</i> in excluding TB drug resistance in a clinical trialM Ejo, A Van Deun, A Nunn, et al.
Annals of Tropical Medicine and Parasitology|July 9, 2009
Zoonotic tuberculosis and brucellosis in Africa: neglected zoonoses or minor public-health issues? The outcomes of a multi-disciplinary workshopT Marcotty, F Matthys, J Godfroid, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Antimicrobial Agents and Chemotherapy|March 16, 2021
Thin-Layer-Agar-Based Direct Phenotypic Drug Susceptibility Testing on Sputum in Eswatini Rapidly Detects Mycobacterium tuberculosis Growth and Rifampicin Resistance Otherwise Missed by WHO-Endorsed Diagnostic TestsE Ardizzoni, E Ariza, D Mulengwa, et al.
Antimicrobial Agents and Chemotherapy|April 9, 2025
Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis-experiences from ArmeniaE Ardizzoni, W Mulders, M De Diego Fuertes, et al.
Journal of Clinical Microbiology|March 3, 2025
Direct thin-layer agar for bedaquiline-susceptibility testing of <i>Mycobacterium tuberculosis</i> at BSL2 level yields high accuracy in 15 days from sputum processingI Cuella-Martin, D Runyambo, S De Bock, et al.
Journal of Clinical Microbiology|September 10, 2020
Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical StrainsS Battaglia, A Spitaleri, A M Cabibbe, et al.
IJTLD Open|August 18, 2025
Using linezolid as a substitute for the injectable in case of ototoxicity is safer and as effective as all-oral treatment for rifampicin-resistant TBM B Souleymane, T Decroo, A Soumana, et al.
IJTLD Open|January 19, 2026
Fifteen years of rifampicin-resistant TB control in Niger: high countrywide treatment uptake and successI Maman Lawan, T Decroo, M B Souleymane, et al.
IJTLD Open|November 17, 2025
High-dose amikacin in the first week of all-oral rifampicin-resistant TB treatment is safe: a single-arm trialJ Snobre, J Gasana, T Decroo, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|April 2, 2020
Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in RwandaJ-C S Ngabonziza, Y M Habimana, T Decroo, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 7, 2021
Effectiveness of GenoType MTBDR<i>sl</i> in excluding TB drug resistance in a clinical trialM Ejo, A Van Deun, A Nunn, et al.
Annals of Tropical Medicine and Parasitology|July 9, 2009
Zoonotic tuberculosis and brucellosis in Africa: neglected zoonoses or minor public-health issues? The outcomes of a multi-disciplinary workshopT Marcotty, F Matthys, J Godfroid, et al.
Pageof 9